Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Commentary: Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis
Esteban Dauden-Tello, MD, PhD
Department of Dermatology, Hospital Universitario de la Princesa
Madrid, Spain
PUBLICATION
1. Prevalence and Factors Associated with Sleep Disturbance in Adult Patients with Psoriasis. Sahin e, M Hawro, Weller K, et al. J Eur Acad Dermatol Venereol. 2022 May;36(5):688-697. doi: 10.1111/jdv.17917. Epub 2022 Mar 8. PMID: 35020226.
Why this article was chosen
Commentary
Sleep disorders have a high prevalence in patients with psoriasis and significantly impact their physical and psychological well-being. The relationship between sleep disorders and psoriasis has been analyzed in numerous studies but remains poorly understood, primarily due to potential confounding factors such as pruritus, anxiety, or depression.
In this article, researchers from Berlin and Lübeck (Germany) dive deeper into understanding the impact of sleep disturbances in patients with psoriasis to identify clinical, demographic, and psychological factors. Using validated questionnaires for evaluating sleep and other measurements of quality of life, they compared psoriasis patients with a group of healthy individuals.
The significant findings of their study revealed that the prevalence of sleep disturbances was higher in psoriasis patients, and sleep was more impaired compared to healthy subjects. No association between sleep disturbance and psoriasis severity was observed, although most patients with sleep disturbances had well-controlled mild psoriasis. Other findings include observations that intense pruritus that occurred at bedtime was associated with impaired sleep (probably due to direct interference with sleep). Sleep disturbances were associated with anxiety, depression, and diminished health-related quality of life, particularly in female psoriasis patients. Increased levels of anxiety and depression were the main predictors of sleep impairment (better than pruritus parameters altogether).
The limitation of the current study includes the inability to define a causal relationship between sleep disturbances and their associated factors. However, it does not detract from the merits of this study that helps us better understand sleep disorders in patients with psoriasis, raising the possibility that complementary psychotherapy aimed at reducing anxiety, depression, and psychological distress may help to improve sleep in our patients.
Categories
Recent Posts
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis
Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study
IFPA and IPC Partnership One Year Later — Joining the Clinical and Patient Perspectives
Also Read
Commentary: Trajectories and Prognosis after Discontinuation of Biologics due to Remission in Psoriasis – A Nationwide Cohort Study
The prognosis and maintenance of response after treatment discontinuation following remission lack proper characterization. Real-world data obtained from national registries may provide valuable insights into this clinical issue. Tiago Torres, MD, PhD, provides his expert opinion on a recent study that investigated epidemiological characteristics and disease markers during the first two years following cessation of biologic therapy due to remission in adult patients.
Commentary: Association of Apremilast with Vascular Inflammation and Cardiometabolic Function in Patients with Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial
Recently, a study was conducted on the effect of apremilast on vascular inflammation and cardiometabolic functions with an impressively comprehensive set of markers for vascular inflammation and cardiometabolic disease. Peter van de Kerkhof, MD, PhD, provides his expert opinion on the overall conclusion and the implications of this study are discussed.
Commentary: Deucravacitinib Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Efficacy and Safety Results from the 52-week, Randomized, Double-blinded, Placebo-controlled Phase 3 POETYK PSO-1 Trial
The United States Food and Drug Administration (FDA) has approved deucravacitinib to treat psoriasis. Recently, 52-week efficacy and safety data of deucravacitinib were compared and contrasted with placebo and apremilast. The outcome of this comparative study lends support for the position of deucravacitinib in the spectrum of treatments for psoriasis.
Subscribe to the IPC Newsletter